oru.sePublikationer
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
The risk of HCV RNA contamination in serology screening instruments with a fixed needle for sample transfer
Linkoping Univ, Dept Clin & Expt Med, Div Infect Dis, S-58183 Linkoping, Sweden..
Linkoping Univ, Dept Clin & Expt Med, Div Infect Dis, S-58183 Linkoping, Sweden..
Linkoping Univ, Dept Clin & Expt Med, Div Infect Dis, S-58183 Linkoping, Sweden..
Orebro University Hospital. Division Clinical Microbiology.
Show others and affiliations
2014 (English)In: Journal of Clinical Virology, ISSN 1386-6532, E-ISSN 1873-5967, Vol. 60, no 2, 172-173 p.Article in journal (Refereed) Published
Abstract [en]

Background: Hepatitis C diagnostics involve antibody screening and confirmation of current infection by detection of HCV RNA positivity. In screening instruments with fixed pipetting needle, there is a risk of sample carry-over contamination.

Objectives: The aim of this study was to evaluate the risk of such contamination in a proposed clinical setting. Study design: In the present study, known HCV RNA positive (n = 149) and negative (n = 149) samples were analysed by anti-HCV Abbott in an Architect instrument in an alternating fashion in order to test for contamination.

Results: In subsequent retesting of the previously HCV RNA-negative samples, six samples (4%) were positive by the Cobas Taqman assay with a maximum level of 33 IU/mL. The results show that there is a risk for transfer of HCV in the Architect instrument but they also show that the levels of HCV RNA observed are low.

Conclusions: We conclude that complementary HCV RNA testing on samples identified as anti-HCV positive by screening can be recommended because the complementary results are reliable in the majority of cases when either HCV RNA is negative or HCV RNA is positive with a level > 1000 IU/mL. In a minority of cases, with low HCV RNA after anti-HCV antibody screening, cross-contamination should be suspected and a new sample requested for HCV RNA testing. This strategy would reduce the need for obtaining a new sample from the vast majority of patients with a newly discovered HCV antibody positivity. (C) 2014 The Authors. Published by Elsevier B.V

Place, publisher, year, edition, pages
Elsevier, 2014. Vol. 60, no 2, 172-173 p.
Keyword [en]
HCV, Contamination, Screening
National Category
Infectious Medicine
Identifiers
URN: urn:nbn:se:oru:diva-56710DOI: 10.1016/j.jcv.2014.03.011ISI: 000335738000016PubMedID: 24735614Scopus ID: 2-s2.0-84900332850OAI: oai:DiVA.org:oru-56710DiVA: diva2:1083797
Available from: 2017-03-22 Created: 2017-03-22 Last updated: 2017-03-22Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMedScopus

Search in DiVA

By author/editor
Sundqvist, MartinSerrander, Lena
By organisation
Orebro University Hospital
In the same journal
Journal of Clinical Virology
Infectious Medicine

Search outside of DiVA

GoogleGoogle Scholar

Altmetric score

Total: 2 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • harvard1
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf